 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...2324252627282930313233...8687» |
- Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network. (Available On Demand; Poster Bd #: A1) - Sep 15, 2022 - Abstract #ASCOQC2022ASCO_QC_318;
Even small shifts in utilization towards LCA can generate a significant reduction in TCOC. Physician-supported, pharmacist-led TIC initiatives are critical to bending the cost curve within Oncology.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Real-world variability in use of bone-modifying drugs for multiple myeloma by payer type. (Available On Demand; Poster Bd #: D28) - Sep 15, 2022 - Abstract #ASCOQC2022ASCO_QC_214;
Differences in request for BMA across payer types suggests variability in adherence to guidelines may be based on patient insurance. To achieve equitable outcomes, including for patients of lower socioeconomic status, targeted efforts must be put in place to ensure receipt of guideline-directed therapy.
- Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network. (Available On Demand) - Sep 15, 2022 - Abstract #ASCOQC2022ASCO_QC_93;
Even small shifts in utilization towards LCA can generate a significant reduction in TCOC. Physician-supported, pharmacist-led TIC initiatives are critical to bending the cost curve within Oncology.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases. (Pubmed Central) - Sep 14, 2022
Our results confirm (for the first time) the activation of PDGFRβ on mononuclear stromal/tumor cells at protein level as an effect of denosumab treatment, which has so far only been demonstrated by phosphoprotein array analysis (protein lysates). The decreased PDGFRβ activity after the discontinuation of denosumab treatmeant and the increased PDGFRβ activity during denosumab treatment underlines the need for denosumab and sunitinib combination therapy.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center. (Pubmed Central) - Sep 14, 2022
The risk of spontaneously developing MRONJ was low. Risk of developing MRONJ was found to be higher when dentoalveolar procedures performed within 3 week before starting antiresorptive medications.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine. (Pubmed Central) - Sep 14, 2022
Risk of developing MRONJ was found to be higher when dentoalveolar procedures performed within 3 week before starting antiresorptive medications. Non-adherent patients and new non-traumatic fractures (including rebound fractures) were more prevalent during the lockdown in comparison to the pre-COVID-19 period, regardless of the modality of medical evaluation.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial. (Pubmed Central) - Sep 14, 2022
This provides a possible explanation for the rebound effect on bone turnover markers as well as bone mineral density (BMD) upon withdrawal of denosumab. None of the other measured markers of inflammation was influenced by denosumab treatment.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, HEOR: Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia. (Pubmed Central) - Sep 14, 2022
None of the other measured markers of inflammation was influenced by denosumab treatment. From the perspective of the Malaysian health care provider, denosumab appears to be a cost-effective treatment choice for postmenopausal osteoporotic women over 60 years of age.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. (Pubmed Central) - Sep 14, 2022
Risk of MVF after DMAb discontinuation increases with increased duration of DMAb treatment. Patients transitioning off DMAb after 3?years may warrant more frequent administration of zoledronic acid or another bisphosphonate to maintain bone turnover and BMD and prevent MVF.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Journal: Osteoporosis in hemophilia: what is its importance in clinical practice? (Pubmed Central) - Sep 14, 2022
They include the use of antiresorptives (estrogens, selective estrogen receptor modulators, bisphosphonates, denosumab) and anabolic agents (teriparatide, abaloparatide, romosozumab). Further studies on the management of osteoporosis in patients with hemophilia are required.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab, an effective osteoporosis treatment option for men. (Pubmed Central) - Sep 14, 2022
Further studies on the management of osteoporosis in patients with hemophilia are required. No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: The efficacy of denosumab in Korean male patients with osteoporosis. (Pubmed Central) - Sep 14, 2022
No abstract available Our study indicates that denosumab is effective in increasing BMD in Korean osteoporosis males regardless of prior bisphosphonate treatment.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial. (Pubmed Central) - Sep 14, 2022
However, given the known rebound affects after discontinuation of denosumab treatment, these effects cannot be expected to persist. If prolonged treatment or shift to other regimes would be beneficial to reduce the risk of cup loosening is yet to be investigated.
- || Xofigo (radium Ra-223 dichloride) / Bayer
Review, Journal: Bone Health Management in the Continuum of Prostate Cancer Disease. (Pubmed Central) - Sep 13, 2022
However, these diagnostics and treatment options are not very accurate nor efficient enough to treat bone metastases and manage bone health. In this review, we present the pathogenesis of PCa-induced bone metastasis, its deleterious impacts on vital organs, the impact of metastatic PCa on bone health, treatment interventions for bone metastasis and management of bone- and skeletal-related events, and possible current and future therapeutic options for bone management in the continuum of prostate cancer disease.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Sadly, paywalled. And those of us on denosumab, which suppresses B- and T-cells have no guidance whatsoever. The MD who prescribes mine said he had no idea it affected immune sx and so I'm on my own. Day 908 of isolation because what else can I do? (Twitter) - Sep 12, 2022
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Ibrance (palbociclib) / Pfizer
AN UNCOMMON CAUSE OF CHEST PAIN: CEMENT EMBOLISM (Convention Center Exhibit Hall: Poster Area) - Sep 11, 2022 - Abstract #CHEST2022CHEST_4085;
Fortunately majority of them are peripheral, asymptomatic and only need surveillance. For symptomatic, central pulmonary cement embolism long term anticoagulation therapy has been recommended.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk. (Pubmed Central) - Sep 10, 2022
For symptomatic, central pulmonary cement embolism long term anticoagulation therapy has been recommended. No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk. (Pubmed Central) - Sep 10, 2022
No abstract available No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Observational data, Journal, Real-world evidence: Real-world effectiveness of osteoporosis treatments in Germany. (Pubmed Central) - Sep 10, 2022
No abstract available Continued treatment with osteoporosis medications was associated with reductions of fracture rates in a real-world setting.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT () - Sep 9, 2022 - Abstract #CTOS2022CTOS_370;
Adults with ARMS have a very poor prognosis due to the advanced stage of the disease at diagnosis and the high metastatic potential. A multidisciplinary approach to these patients with surgery when feasible, CT and RT is the best current therapy, though long-term survivors remain poor.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Immunohistochemical Expression of H3.3G34W in a Series of Giant Cell Tumors of The Bone: A Single Institutional Study at a Tertiary Cancer Referral Center ([IN-PERSON]) - Sep 8, 2022 - Abstract #CAP2022CAP_865;
This study, constituting one of the first reports from our country, further validates the value of H3.3G34W in differentiating GCTB, including metastatic and malignant GCTB, from its diagnostic mimics. Its utility in identifying residual tumor cells in post–denosumab-treated GCTBs is worth exploring.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Immunohistochemical Expression of H3.3G34W in a Series of Giant Cell Tumors of The Bone: A Single Institutional Study at a Tertiary Cancer Referral Center ([IN-PERSON]) - Sep 8, 2022 - Abstract #CAP2022CAP_266;
This study, constituting one of the first reports from our country, further validates the value of H3.3G34W in differentiating GCTB, including metastatic and malignant GCTB, from its diagnostic mimics. Its utility in identifying residual tumor cells in post–denosumab-treated GCTBs is worth exploring.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Zoledronic acid >>>>>> Denosumab We have been giving it monthly for the first 12 months, then we switch to Q3 months or stop the zoldrea. 3 monthly is non- inferior to monthly I believe. @NicoGagelmann what's your practice ?? (Twitter) - Sep 8, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Zoledronate ftw! Does anybodybuse denosumab? (Twitter) - Sep 8, 2022
- || Empliciti (elotuzumab) / AbbVie, BMS, Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Denosumab is like elotuzumab, nice name but just not worth it. We use zoledronic acid monthly for 6 months, assess status continuously and then stop or swith to Q3 months. (Twitter) - Sep 8, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, odanacatib (MK-0822) / Merck (MSD)
Journal: Diabetes mellitus and the benefit of antiresorptive therapy on fracture risk. (Pubmed Central) - Sep 7, 2022
However, when we considered trials individually, we found a few interactions within individual studies between diabetes status and the effects of denosumab and odanacatib on fracture risk, change in BMD or BTM. In sum, these results provide strong evidence that bisphosphonates and most licensed antiresorptive drugs are effective at reducing fracture risk and increasing BMD irrespective of diabetes status.
- Avastin (bevacizumab) / Roche
Osteonecrosis of the Jaw Associated With Bevacizumab in Treatment: A Case Series Using the FDA Adverse Event Reporting System (FAERS) Database (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_2362;
146 cases (1.5%) of bevacizumab associated with ONJ were identified. 65.8% (96) of the patients were female and the average age was 60.9 years +/- 9.3 years.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab for prevention of acute onset immobilization-induced alterations of bone turnover: a randomized controlled trial. (Pubmed Central) - Sep 4, 2022
No adverse events could be attributed to the study medication. The investigation proved that a single application of denosumab early after admission to an ICU prevents acute immobilization-associated increase in bone resorption among previously healthy individuals.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: The use of bone-modifying agents in multiple myeloma. (Pubmed Central) - Sep 3, 2022
Treatment of myeloma bone disease includes bisphosphonates or denosumab (bone-modifying agents)...While these agents improve quality of life, it is not known whether they improve overall survival. This review focuses on different classes of bone-modifying agents, their mechanisms of action, time of initiation, duration of therapy, and potential survival benefits.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Review, Journal: The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Sep 3, 2022
For patients with asymptomatic PHPT, surgery usually achieves biochemical cure. These results can help to inform patients and clinicians regarding use of medical therapy and surgery in PHPT.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: The role of bone mineral density in adult spinal deformity patients undergoing corrective surgery: a matched analysis. (Pubmed Central) - Sep 3, 2022
These results can help to inform patients and clinicians regarding use of medical therapy and surgery in PHPT. Patients with ASD undergoing multilevel thoracolumbar fusion surgery have significantly higher rates of postoperative pseudarthrosis, proximal and distal junctional kyphosis, and revision surgery rates compared to patients with normal BMD.
- |||||| AVT03 (denosumab biosimilar) / Alvotech, Dr. Reddy's
Enrollment open: Multicenter Study in Postmenopausal Women with Osteoporosis, ALVOBOND (clinicaltrials.gov) - Sep 2, 2022
P3, N=476, Recruiting, Sponsor: Alvotech Swiss AG
Patients with ASD undergoing multilevel thoracolumbar fusion surgery have significantly higher rates of postoperative pseudarthrosis, proximal and distal junctional kyphosis, and revision surgery rates compared to patients with normal BMD. Not yet recruiting --> Recruiting
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical: MGH does not have denosumab on inpt formulary though providers can request the medication through non-form request process. Decreasing dose/extending infusion duration of ZA is weighed against denosumab case by case by @andrew02114 and @NoopurRajeMD. (Twitter) - Sep 2, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Journal, HEOR: Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk. (Pubmed Central) - Sep 1, 2022
Not yet recruiting --> Recruiting Among PMO patients with a very high fracture risk in the US, zoledronate is the cheapest strategy and denosumab is the most cost-effective choice among these five strategies.
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Clinical: Very helpful - thank you 🙏 it can be hard to discern what’s causing AKI at times, but that’s def an advantage. Does MGH have Xgeva on inpatient formulary? I will say that it’s a moot point for us since Zometa the only option… and so we normally just drop the dose here! (Twitter) - Sep 1, 2022
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Clinical: Moreover, denosumab less likely than zoledronic acid to worsen renal function, especially in patients with underlying kidney dysfunction. Table from randomized study https://t.co/ITuY5m1W7V (Twitter) - Sep 1, 2022
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Arguments for using denosumab: faster time to response, 2 v. 3 days. The faster response can be helpful where hypercalcemia is mediating altered mental status or renal dysfunction. (Twitter) - Sep 1, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Soooo…those that have taken Xgeva are screwed? Nice to read this on Twitter (Twitter) - Sep 1, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Observational data, Journal, Real-world evidence: Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting. (Pubmed Central) - Aug 31, 2022
Among PMO patients with a very high fracture risk in the US, zoledronate is the cheapest strategy and denosumab is the most cost-effective choice among these five strategies. Rebound-associated bone loss reached a plateau after denosumab treatment durations of 4-6 years, irrespective of the frequency of subsequent zoledronate therapy.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Check this out #myeloma RT @RahulBanerjeeMD: Nice @MGHCancerCenter analysis of Xgeva vs Zometa for #MMsm hypercalcemia. Xgeva pricier, more likely to cause hypo… https://t.co/sMFyhqlPM7 (Twitter) - Aug 31, 2022
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Seen severe hypophosphatemia with Xgeva too! (Twitter) - Aug 31, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Review, Journal: The Effect of Denosumab and Risk Factors for Recurrence in Spinal Giant Cell Tumors: A Systematic Review and Meta-Analysis. (Pubmed Central) - Aug 30, 2022
So far, many researchers have used denosumab in spinal GCT, but none have clearly suggested an endpoint. Most studies, however, recommend using it for more than 6 months.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Head-to-Head: Agree 100 % Xgeva approval was based on an non inferiority travel and excluded pts with CKD If I am not mistaken it was presented at one of the conferences in Mumbai / india 🇮🇳 (Twitter) - Aug 30, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma. (Pubmed Central) - Aug 30, 2022
Most studies, however, recommend using it for more than 6 months. No abstract available
- ||||| FKS518 (denosumab biosimilar) / Fresenius Kabi
Enrollment closed, Trial completion date, Trial primary completion date: LUMIADE-3: A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Aug 30, 2022
P3, N=553, Active, not recruiting, Sponsor: Fresenius Kabi SwissBioSim GmbH
No abstract available Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Mar 2023 --> Jul 2023
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
مرضى السرطان الذين يعانون من انتشار ثانويات سرطانية للعظام .. كثيراً ما يُصرف له حُقن علاجية تعمل على تقليل تآكل العظام المرافق للانتشار السرطاني هناك .. ومن أبرز هذه الأدوية: ١- الدينوسوماب (denosumab) كإبر تحت الجلد كل ٤ أسابيع ٢- الزوميتا (zometa) كإبر وريدية كل ٣-٤ أسابيع (Twitter) - Aug 29, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment. (Pubmed Central) - Aug 27, 2022
Significant increases in % COPs were observed after 12 months of treatment with Dmb (21.9%) and TPTD (17%). These results can be related to an increase in osteogenesis and, consequently, a better and more efficient repair of bone tissue.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand. (Pubmed Central) - Aug 27, 2022
The monoclonal antibody denosumab successfully inhibited the maturation of osteoclasts (OCs) by binding to RANKL in the clinic...Moreover, Y1693 demonstrated good tolerability and efficacy in an orally administered mouse model of osteoporosis as well as the ability to rescue alveolar bone loss in vivo caused by periodontal disease. Collectively, the above findings may provide a valuable direction for the development of novel antiresorptive therapies that target RANKL.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Me and my grandmother went on a trip, and on our trip we took: Denosumab Tagging: @AKesarwala @pipcosper (Twitter) - Aug 26, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal. (Pubmed Central) - Aug 26, 2022
Collectively, the above findings may provide a valuable direction for the development of novel antiresorptive therapies that target RANKL. No abstract available